US2016263164A1PendingUtilityA1
Composition and method to alleviate joint pain using phospholipids and roe extract
Assignee: U S NUTRACEUTICALS LLC D/B/A VALENSA INTPriority: Jul 23, 2009Filed: May 24, 2016Published: Sep 15, 2016
Est. expiryJul 23, 2029(~3 yrs left)· nominal 20-yr term from priority
A61K 35/60A23L 1/30A61K 31/202A23V 2002/00A61K 31/661A23L 1/296A61K 31/122A61K 36/535A23L 1/3006A61K 2236/37A23L 1/3008A61K 31/728A61K 31/685A61K 36/9066A61K 31/7028A23L 33/40A23L 33/12A61K 36/324A23L 33/10A23L 33/115A61K 45/06A61K 35/612A61K 9/4858A61K 36/05
48
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A dietary supplement composition and associated method has its composition formulated in a therapeutic amount to treat and alleviate symptoms of joint pain in a person having joint pain. The composition includes astaxanthin, low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan) having a molecular weight of 0.5 to 300 kilodaltons (kDa), and a phospholipid rich egg roe extract having phospholipid bound EPA and DHA admixed with seed and/or fish oil having an ALA to LA ratio of 1:1 to 6:1 and in an oral dosage form.
Claims
exact text as granted — not AI-modifiedThat which is claimed is:
1 . A method to treat and alleviate symptoms of joint pain in a person having joint pain by administering to a person a therapeutic amount of a dietary supplement composition comprising astaxanthin, low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan) having a molecular weight of 0.5 to 300 kilodaltons (kDa), and a phospholipid rich egg roe extract admixed with seed oil having an alpha-linolenic acid (ALA) to linoleic acid (LA) ratio of 1:1 to 6:1 and in an oral dosage form.
2 . The method according to claim 1 , wherein the phospholipid rich egg roe extract admixed with seed oil contains phospholipid bound EPA and DHA.
3 . The method according to claim 1 , wherein the low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan) comprises pro-inflammatory low molecular weight microbial fermented sodium hyaluronate fragments.
4 . The method according to claim 1 , wherein the low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan) has a molecular weight of 0.5 to 100 kDa.
5 . The method according to claim 1 , wherein the phospholipid rich egg roe extract admixed with seed oil comprises about 15 to about 60 percent phospholipids.
6 . The method according to claim 1 , wherein the phospholipid rich egg roe extract admixed with seed oil comprises Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) fatty acids wherein the amount of DHA is at least 50 percent greater than the amount of EPA.
7 . The method according to claim 1 , wherein the phospholipid rich egg roe extract admixed with seed oil includes triacyglycerides.
8 . The method according to claim 1 , further comprising an antioxidant.
9 . The method according to claim 1 , wherein the dietary supplement composition is formulated into a single dosage capsule.
10 . The method according to claim 1 , further comprising forming the seed oil by supercritical CO2 fluid extracting seed oil from a cracked biomass of perilla frutescens.
11 . A method to treat and alleviate symptoms of joint pain in a person having joint pain by administering to a person a therapeutic amount of a dietary supplement composition comprising astaxanthin, low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan) having a molecular weight of 0.5 to 300 kilodaltons (kDa), and a phospholipid rich egg roe extract admixed with a supercritical CO2 fluid extracted perilla seed oil derived from a cracked biomass of perilla frutescens , the seed oil comprising from 60 to 95 percent w/w of PUFAs and the phospholipid rich egg roe extract admixed with seed oil having an alpha-linolenic acid (ALA) to linoleic acid (LA) ratio of 1:1 to 6:1 and in an oral dosage form.
12 . The method according to claim 11 , wherein the phospholipid rich egg roe extract admixed with seed oil contains phospholipid bound EPA and DHA.
13 . The method according to claim 11 , wherein the low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan) comprises pro-inflammatory low molecular weight microbial fermented sodium hyaluronate fragments.
14 . The method according to claim 11 , wherein the low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan) has a molecular weight of 0.5 to 100 kDa.
15 . The method according to claim 11 , wherein the phospholipid rich egg roe extract admixed with seed oil comprises about 15 to about 60 percent phospholipids.
16 . The method according to claim 11 , wherein the phospholipid rich egg roe extract admixed with seed oil comprises Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) fatty acids wherein the amount of DHA is at least 50 percent greater than the amount of EPA.
17 . The method according to claim 11 , wherein the phospholipid rich egg roe extract admixed with seed oil includes triacyglycerides.
18 . The method according to claim 11 , further comprising an antioxidant.
19 . The method according to claim 11 , wherein the dietary supplement composition is formulated into a single dosage capsule.
20 . The method according to claim 11 , further comprising forming the seed oil by supercritical CO2 fluid extracting seed oil from a cracked biomass of perilla frutescens , the perilla seed oil comprising from 60 to 95 percent w/w of PUFAs in a ratio from 4:1 to 6:1 alpha-linolenic acid (ALA) to linoleic acid (LA).Join the waitlist — get patent alerts
Track US2016263164A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.